Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B.
ABOUT US
Executive Team
Our management team has broad expertise across scientific and business operations, inventing compounds, and advancing product candidates through clinical development.
Senior Leadership Team
Board of Directors
Scientific Advisory Boards
Obesity
NASH
Partnerships
We believe strategic partnerships break barriers to innovation and we continuously evaluate partnership opportunities. Contact Raymond Jordt, Chief Business Officer, for partnership inquiries.
For partnership opportunities contact:
Raymond Jordt
Chief Business Officer
rjordt@altimmune.com
